
To claim CME credit, successfully complete this case-based posttest online at <https://digital-catalog.aad.org/diweb/catalog/t/12952/o/-esd>. Note: CME quizzes are available after the first of the month in which the article is published. If you have any questions, please contact the Member Resource Center of the American Academy of Dermatology toll-free at (866) 503-SKIN (7546), (847) 240-1280 (for international members), or by e-mailing mrc@aad.org.

CME examination

Identification No. JB0520

May 2020 issue of the Journal of the American Academy of Dermatology.

Goldburg SR, Strober BE, Payette MJ. J Am Acad Dermatol 2020;82:1061-82.

Directions for questions 1-3: Choose the single best response.

A 19-year-old woman presents with a new diagnosis of hidradenitis suppurativa (HS). After your examination, you conclude that she has Hurley stage I disease.

1. Based on this diagnosis and classification, which of the following is a treatment for this patient that has been approved by the US Food and Drug Administration?
 - a. Clindamycin/rifampin
 - b. Dapsone
 - c. Intralesional kenalog
 - d. Adalimumab
 - e. None of these therapies is approved by the US Food and Drug Administration for this patient

A 35-year-old man with moderate to severe HS arrives for his 12-week follow up. He initially presented with 2 abscesses, 12 inflammatory nodules, and 1 draining fistula, at which time he started treatment with adalimumab 160 mg at week 0, 80 mg at week 2, and 40 mg weekly starting at week 4.

2. Which of the following examination findings at his follow-up appointment would deem him a responder using the Hidradenitis Suppurativa Clinical Response?
 - a. Two abscesses, 8 inflammatory nodules, and 1 draining fistula
 - b. Three abscesses, 1 inflammatory nodule, and no draining fistulae
 - c. Two abscesses, 3 inflammatory nodules, and 1 draining fistula
 - d. One abscess, 4 inflammatory nodules, and 2 draining fistulae
 - e. Two abscesses, 0 inflammatory nodules, and 2 draining fistulae

You are evaluating a new patient who is a 20-year-old man with mild to moderate HS.

3. Although isotretinoin has not been approved by the US Food and Drug administration for the treatment of HS, some studies suggest that it is beneficial in patients with which of the following characteristics?
 - a. Patients who are younger, have a low body mass index, have severe acne, and have mild HS
 - b. Patients who are younger, have a high body mass index, have mild acne, and have moderate HS
 - c. Patients who are younger, have a low body mass index, have severe acne, and have severe HS
 - d. Patients who are older, have a low body mass index, have moderate acne, and have mild HS
 - e. Patients who are older, have a low body mass index, have severe acne, and have mild HS